alpha-aminopyridine has been researched along with pf 00299804 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eisenstein, M | 1 |
| de Bruijn, P; Dingemans, AC; Koolen, SLW; Mathijssen, RHJ; Veerman, GDM | 1 |
2 other study(ies) available for alpha-aminopyridine and pf 00299804
| Article | Year |
|---|---|
New lung-cancer drugs extend survival times.
Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis | 2020 |
To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Topics: Aminopyridines; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Indoles; Lactams; Lactams, Macrocyclic; Pyrazoles; Pyrimidines; Quinazolinones; Reproducibility of Results; Sulfones; Tandem Mass Spectrometry | 2021 |